"MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate, AFREZZA, a rapid-acting insulin that has completed Phase III clinical trials for the treatment of diabetes in the United States, Europe, and Japan. The company is also preparing to initiate a Phase II study of MKC1106-MT in patients with advanced melanoma. Its products also include MKC253 (GLP-1), a Phase I clinical trials product for the treatment of type 2 diabetes; and MKC1106-PP, a Phase I clinical trials product for the treatment of diverse tumor types, metastatic diseases, and/or progressive, refractory disease. In addition, the company conducts preclinical studies of drug candidates, MKC204, which may have the potential to treat certain malignancies and inflammatory diseases; MKC180, an obesity compound; and MKC1106-NS, a cancer immunotherapy product. MannKind Corporation was founded in 1991 and is based in Valencia, California."